[
    [
        {
            "time": "",
            "orginal_text": "“基因测序第一股”华大基因去年营收突破20亿元",
            "features": {
                "keywords": [
                    "华大基因",
                    "基因测序",
                    "营收"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技",
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "“基因测序第一股”华大基因去年营收突破20亿元",
            "scores": {
                "News_content": "“基因测序第一股”华大基因去年营收突破20亿元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药(02196.HK)订立两项框架协议",
            "features": {
                "keywords": [
                    "复星医药",
                    "框架协议"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制药",
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "复星医药(02196.HK)订立两项框架协议",
            "scores": {
                "News_content": "复星医药(02196.HK)订立两项框架协议",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "中国医药行业企业集团十强名单公布 这几家你一定熟",
            "features": {
                "keywords": [
                    "医药行业",
                    "十强名单"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "行业排名"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "original_text": "中国医药行业企业集团十强名单公布 这几家你一定熟",
            "scores": {
                "News_content": "中国医药行业企业集团十强名单公布 这几家你一定熟",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "看好中国 | 健康中国 ——创新药机会依旧",
            "features": {
                "keywords": [
                    "健康中国",
                    "创新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "政策导向"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "看好中国 | 健康中国 ——创新药机会依旧",
            "scores": {
                "News_content": "看好中国 | 健康中国 ——创新药机会依旧",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "港股医药股集体走高 东阳光药大涨逾10%",
            "features": {
                "keywords": [
                    "港股",
                    "医药股",
                    "东阳光药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "港股市场"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "港股医药股集体走高 东阳光药大涨逾10%",
            "scores": {
                "News_content": "港股医药股集体走高 东阳光药大涨逾10%",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "orginal_text": "泰凌医药反弹4% 取得骨质疏松药星马泰等独家经营权",
            "features": {
                "keywords": [
                    "泰凌医药",
                    "骨质疏松药",
                    "独家经营权"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "药品经营权"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "泰凌医药反弹4% 取得骨质疏松药星马泰等独家经营权",
            "scores": {
                "News_content": "泰凌医药反弹4% 取得骨质疏松药星马泰等独家经营权",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]